Promising initial results from the IMBRAVE050 trial fell through after longer follow-up.
after resection or ablation showed a 28% improvement in recurrence-free survival at a medium follow-up of 17.4 months. the 2024 European Society for Medical Oncology Congress
In the trial, 668 patients with HCC at high risk for relapse after surgery or thermal ablation were randomized to atezolizumab 1200 mg plus bevacizumab 15 mg/kg every 3 weeks or to active surveillance for 1 year. Patients in the active surveillance group could crossover to the treatment group following a protocol-defined recurrence event. was the most common HCC etiology. Most participants initially had a solitary tumor treated with resection.
There were no new safety signals with longer follow-up. Over one third of patients in the atezolizumab/bevacizumab group had a grade 3/4 treatment-related adverse event, and there were two treatment-related deaths.
HCC - Hepatocellular Carcinoma Liver Cancer HCC Hepatocellular Cancer Cancer Of The Liver Liver Carcinoma Carcinoma Of The Liver Antiangiogenesis Angiogenesis Inhibitor Bevacizumab Humanized Monoclonal Antibody Bevacizumab Trastuzumab Humanised Monoclonal Antibody Biologic Therapy Biologics Ablation Resection Adjuvant Setting Angiogenesis Cancer
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer IndicationsSubcutaneous injections save time, taking about 7 minutes, vs 30-60 minutes for intravenous infusion.
Read more »
Exploratory Data Support Both Adjuvant and Neoadjuvant Nivolumab for NSCLCInvestigators analyzed patient-level data from the phase 3 CheckMate 77T and 816 trials.
Read more »
No DFS Benefit With Adjuvant Durvalumab in Early NSCLCThe lack of a disease-free survival benefit with adjuvant durvalumab in early-stage resected non-small cell lung cancer in the CCTG BR.31 trial underscores the need to identify biomarkers.
Read more »
Adjuvant Everolimus Offers No Survival Benefit in Non–Clear Cell RCCA secondary analysis of the EVEREST trial found that adjuvant everolimus did not provide a recurrence-free or overall survival benefit in patients with localized non–clear cell RCC.
Read more »
Should All Patients With Early Breast Cancer Receive Adjuvant Radiotherapy?Researchers analyzed data from patients with early breast cancer who were randomized to receive high-dose or no radiotherapy.
Read more »
Apple iPhone 16 Plus Preview: Is the Plus model still needed?Mariyan, a tech enthusiast with a background in Nuclear Physics and Journalism, brings a unique perspective to PhoneArena. His childhood curiosity for gadgets evolved into a professional passion for technology, leading him to the role of Editor-in-Chief at PCWorld Bulgaria before joining PhoneArena.
Read more »